{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T05:17:12Z","timestamp":1735363032853,"version":"3.32.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejphar.2024.177159","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T23:50:19Z","timestamp":1732837819000},"page":"177159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An antibody against human interleukin-2 showing minimal binding to neonatal Fc receptor: Potent anti-tumor activity and reduced systemic toxicity in mice"],"prefix":"10.1016","volume":"987","author":[{"given":"Yunying","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1141-8452","authenticated-orcid":false,"given":"Zheng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.177159_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ejphar.2024.177159_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1371\/journal.pone.0190084","article-title":"High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features","volume":"12","author":"Achkar","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.177159_bib3","first-page":"732","article-title":"The computationally designed human antibody, AU-007, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 auto-inhibitory loop and preventing Treg expansion","volume":"9","author":"Amit","year":"2021","journal-title":"J. Immunol. Ther. Cancer"},{"key":"10.1016\/j.ejphar.2024.177159_bib4","doi-asserted-by":"crossref","first-page":"22927","DOI":"10.1074\/jbc.M112.355131","article-title":"Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal fc receptor with different affinities that reveal distinct cross-species differences in serum half-life","volume":"287","author":"Andersen","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.177159_bib5","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1126\/scitranslmed.aag3187","article-title":"Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2","volume":"8","author":"Arenas-Ramirez","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2024.177159_bib6","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2024.177159_bib7","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of t cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2024.177159_bib8","first-page":"680","article-title":"NKTR-214, an engineered cytokine with biased IL2 ceceptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Cancer Ther.: Preclinical."},{"key":"10.1016\/j.ejphar.2024.177159_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Deak","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.177159_bib10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2024.177159_bib11","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.177159_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1126\/science.2785715","article-title":"Interleukin-2 receptor \u03b2 chain gene: generation of three receptor forms by cloned human \u03b1 and \u03b2 chain cDNA's","volume":"244","author":"Hatakeyama","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2024.177159_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41577-022-00680-w","article-title":"Engineering IL-2 for immunotherapy of autoimmunity and cancer","volume":"22","author":"Hernandez","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2024.177159_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.immuni.2022.12.012","article-title":"Something old, something new: the marriage of PD-1 and IL-2","volume":"56","author":"Horton","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2024.177159_bib15","first-page":"A1","article-title":"ANV419 is a novel CD122-selective IL-2\/anti-IL-2 antibody fusion protein with potent CD8 T cell and NK cell stimulatory function in vitro and in vivo","volume":"8","author":"Huber","year":"2020","journal-title":"J. Immunol. Ther. Cancer"},{"key":"10.1016\/j.ejphar.2024.177159_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/329160a0","article-title":"Importance of IL-2 receptors in intra-thymic generation of cells expressing T-cell receptors","volume":"329","author":"Jenkinson","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2024.177159_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the national cancer institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejphar.2024.177159_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based","volume":"6","author":"Klein","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejphar.2024.177159_bib19","series-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","first-page":"11906","volume":"107","author":"Krieg","year":"2010"},{"key":"10.1016\/j.ejphar.2024.177159_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2019.1681869","article-title":"TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity","volume":"9","author":"Lee","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejphar.2024.177159_bib22","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","article-title":"In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2","volume":"135","author":"Lotze","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2024.177159_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2024.177159_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60386-7","article-title":"Biology of the interleukin2 receptor","volume":"70","author":"Nelson","year":"1998","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ejphar.2024.177159_bib25","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.it.2023.09.003","article-title":"IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy","volume":"44","author":"Niederlova","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejphar.2024.177159_bib26","doi-asserted-by":"crossref","first-page":"11076","DOI":"10.1073\/pnas.0402970101","article-title":"Exocytosis of IgG as mediated by the receptor, FcRn. An analysis at the single-molecule level","volume":"101","author":"Ober","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2024.177159_bib27","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1073\/pnas.0700337104","article-title":"Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy","volume":"104","author":"Prabhat","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejphar.2024.177159_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered il-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2024.177159_bib29","first-page":"3","volume":"vol. 132","author":"Ren","year":"2022"},{"key":"10.1016\/j.ejphar.2024.177159_bib30","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1038\/s41467-020-20220-1","article-title":"An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer","volume":"11","author":"Sahin","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2024.177159_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1084\/jem.20041982","article-title":"Homeostatic maintenance of natural Foxp3+CD25+CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization","volume":"201","author":"Setoguchi","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2024.177159_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0065-2776(08)60844-5","article-title":"The interleukin 2 receptor","volume":"42","author":"Smith","year":"1988","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.ejphar.2024.177159_bib33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.immuni.2015.04.015","article-title":"Antibodies to interleukin-2 elicit selective t cell subset potentiation through distinct conformational mechanisms","volume":"42","author":"Spangler","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2024.177159_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.immuni.2022.12.006","article-title":"Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor reactive CD8+ T cells and reprogramming macrophages","volume":"56","author":"Tichet","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2024.177159_bib35","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.4049\/jimmunol.0900284","article-title":"In vivo expansion of activated naive CD8 T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy","volume":"183","author":"Tomala","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2024.177159_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10517-011-1268-1","article-title":"Morphofunctional characteristic of the immune system in balb\/c and c57bl\/6 mice","volume":"151","author":"Trunova","year":"2011","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.ejphar.2024.177159_bib37","article-title":"Regulatory T cells suppress the formation of potent KLRK1 and IL-7R expressing effector CD8 T cells by limiting IL-2","volume":"12","author":"Tsyklauri","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ejphar.2024.177159_bib38","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.drudis.2015.09.004","article-title":"Challenges and opportunities for non-antibody scaffold drugs","volume":"20","author":"Vazquez-Lombardi","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2024.177159_bib40","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.1994.12.8.1572","article-title":"Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report","volume":"12","author":"Yang","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2024.177159_bib41","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","article-title":"IL-2R\u03b1-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells","volume":"4","author":"Zou","year":"2023","journal-title":"Nature Cancer"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924008495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924008495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T17:06:54Z","timestamp":1735319214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924008495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":39,"alternative-id":["S0014299924008495"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177159","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An antibody against human interleukin-2 showing minimal binding to neonatal Fc receptor: Potent anti-tumor activity and reduced systemic toxicity in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177159","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177159"}}